| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a9e9ce63eb0bbf3658453fb50a6d9b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b3a00902baf7157c2c4f7a90ec48b907 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2884
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725 |
| filingDate |
1995-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1997-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d88071a8e8bc8539629e3f642df751e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b195d18875a4b3cb2f174c7d93c63015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78b4a1e964a66a52246d6c4b9e21d6b3 |
| publicationDate |
1997-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
DE-19540515-C1 |
| titleOfInvention |
Tumor therapy through adoptive transfer of CD44v-specific cytotoxic T lymphocytes |
| abstract |
The invention concerns a fusion protein containing a first portion having a specific affinity for an amino acid sequence which is coded by a variant exon of the CD44 gene, and a second portion which contains the amino acid sequence of a subunit of the T-cell receptor complex or an immunoglobulin receptor or part of this subunit. Preferably, the first portion contains a variable domain of an antibody which is specific for variant CD44 (CD44v), in particular CD44v6. The invention further concerns a nucleic acid molecule which codes for such a fusion protein. The substances according to the invention are suitable for treating tumours by the adoptive transfer of cytotoxic T-lymphocytes which destroy tumour cells expressing one or a plurality of variant epitopes of the CD44 gene on their cell surface. For example, a nucleic acid molecule according to the invention can be introduced into corresponding lymphocytes and the lymphocytes thus modified can be administered to a patient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9273283-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9181527-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10689617-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10689618-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10689619-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11136549-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9938497-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11034766-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9821011-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9822340-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10682378-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9957480-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10336804-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9790278-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9663763-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11208454-B2 |
| priorityDate |
1995-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |